The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012

Thursday, April 12, 2012

Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 201216:05 EDT Thursday, April 12, 2012TARRYTOWN, N.Y., April 12, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its first quarter 2012 financial and operating results on Thursday, April 26, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EDT that day. Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition.  Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development.  More information and recent news releases are available on the Regeneron website at www.regeneron.com. Contact Information:                                                                                    Manisha Narasimhan, Ph.D.                Peter DworkinInvestor Relations                                Corporate Communications                                914-847-5126                                       914.847.7640                 Manisha.narasimhan@regeneron.com      peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.